PD-1 and PD-L1 Inhibitors Market Size, Share & Trends Analysis Report By Drug Type (Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others), By Disease Type, Region And Segment Forecasts, 2025-2034

Report Id: 1115 Pages: 180 Last Updated: 14 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global PD-1 and PD-L1 Inhibitors Market Segmentation:

Global PD-1 and PD-L1 Inhibitors Market Based on Drug type

  • Atezolizumab
  • Avelumab
  • Cemiplimab
  • Durvalumab
  • Nivolumab
  • Pembrolizumab
  • Sintilimab
  • Others (Pipeline) 

PD-1 and PD-L1 Inhibitors Market

Global PD-1 and PD-L1 Inhibitors Market Based on Disease Type

  • Colorectal Cancer
  • Hodgkins Lymphoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Non-Small-Cell Lung Carcinoma (NSCLC)
  • Renal Cell Carcinoma
  • Urothelial Bladder Cancer
  • Others

Global PD-1 and PD-L1 Inhibitors Market Based on Region

Europe PD-1 and PD-L1 Inhibitors Market by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America PD-1 and PD-L1 Inhibitors Market by Country

  • U.S.
  • Canada

Asia Pacific PD-1 and PD-L1 Inhibitors Market by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America PD-1 and PD-L1 Inhibitors Market by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa PD-1 and PD-L1 Inhibitors Market by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot

Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Clinical Trial/Pipeline Analysis

4.7. Industry Analysis – Porter’s Five Forces Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Key Trends in the Market

Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis

5.1. Drugs Type & Market Share, 2024 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drugs:

5.2.1. Pembrolizumab

5.2.2. Nivolumab

5.2.3. Atezolizumab

5.2.4. Durvalumab

5.2.5. Avelumab

5.2.6. Cemiplimab

5.2.7. Sintilimab

5.2.8. Others

Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis

6.1. Indication Analysis & Market Share, 2024 & 2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

6.2.1. Melanoma

6.2.2. NSCLC

6.2.3. Renal cell carcinoma

6.2.4. Urothelial bladder cancer

6.2.5. Hodgkins Lymphoma

6.2.6. Merkel cell carcinoma

6.2.7. Colorectal cancer

6.2.8. Others

Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Drugs, 2021-2034

7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Indication, 2021-2034

7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Country, 2021-2034

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034

7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034

7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034

7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034

7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034

7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034

7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drug, 2021-2034

7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by country, 2021-2034

7.5.2.1. South Africa

7.5.2.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements

8.2. Funding Activities

8.3. Company Profiles

8.3.1. Merck Co.

8.3.2. Bristol-Myers Squibb

8.3.3. Roche

8.3.4. AstraZeneca

8.3.5. Pfizer

8.3.6. Jiangsu HengRui Medicine

8.3.7. Regeneron Pharmaceuticals

8.3.8. ONO PHARMACEUTICAL CO., LTD.

8.3.9. Eli Lilly and Company

8.3.10. Innovent Biologics, Inc.

8.3.11. BeiGene

8.3.12. Junshi Biosciences Co.

8.3.13. Biocad

8.3.14. 4D pharma plc.

8.3.15. Agenus Inc.

8.3.16. Calithera.

8.3.17. Curis, Inc.

8.3.18. Constellation Pharmaceuticals, Inc.

8.3.19. Compass Therapeutics

8.3.20. Corvus Pharmaceuticals

8.3.21. CytomX Therapeutics, Inc.

8.3.22. eFFECTOR Therapeutics, Inc.

8.3.23. Jounce Therapeutics, Inc.

8.3.24. MacroGenics, Inc.

8.3.25. Mirati Therapeutics, Inc. 

8.3.26. Moderna, Inc.

8.3.27. MultiVir, Inc.

8.3.28. NovoCure Ltd.

8.3.29. NeoImmuneTech, Inc.

8.3.30. Syndax Pharmaceuticals

8.3.31. PrimeVax Immuno-Oncology Inc.

8.3.32. Incyte Corporation

8.3.33. Trillium Therapeutics Inc.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5262
Security Code field cannot be blank!

Frequently Asked Questions

PD-1 and PD-L1 Inhibitors Market Size is valued at USD 48.7 Billion in 2024 and is predicted to reach USD 166.9 Billion by the year 2034

PD-1 and PD-L1 Inhibitors Market is expected to grow at a 13.2% CAGR during the forecast period for 2025-2034.

Merck Co., Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Jiangsu HengRui Medicine, Regeneron Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Eli Li

Drug Type and Disease Type are the key segments of the PD-1 and PD-L1 Inhibitors Market.

North America region is leading the PD-1 and PD-L1 Inhibitors Market.
Get Sample Report Enquiry Before Buying